Cupid Limited Reports 201% YoY EBITDA Growth in Q3 FY26
Filing Summary
Cupid Limited announced its Q3 FY26 financial results, highlighting a 201% year-over-year increase in EBITDA and a 196% rise in net profit. The company’s total income for the quarter reached ₹104 crore, marking a 106% increase from the previous year. The results reflect strong performance across export-led B2B operations and domestic FMCG business. Cupid’s order book is at its highest level, providing multi-year revenue visibility. The company is expanding its FMCG operations into the GCC region and enhancing its diagnostics business with increased production capacity.
Cupid Limited has released its financial results for Q3 FY26, reporting significant growth in key financial metrics. The company’s EBITDA increased by 201% year-over-year, reaching ₹34 crore, while the net profit rose by 196% to ₹33 crore. Total income for the quarter was ₹104 crore, a 106% increase compared to Q3 FY25. The results were driven by strong execution and demand across its business segments.
The company’s financial performance was supported by a robust order book and improved execution visibility. The operating income for Q3 FY26 was ₹94 crore, reflecting a 102% increase from the previous year. The EBITDA margin improved to 37%, up from 25% in Q3 FY25. The net profit margin also increased to 35%, compared to 24% in the same period last year.
Cupid Limited’s operational momentum remains strong, with significant contributions from its export-led B2B operations and domestic FMCG business. The company has a high order book level, driven by long-duration international public health programs and repeat institutional customers. The export business continues to be a key driver, with significant orders from markets such as South Africa, Tanzania, and Brazil.
The company is expanding its FMCG operations, with plans to establish a manufacturing facility in Saudi Arabia to serve the GCC and Middle East markets. This expansion aims to enhance Cupid’s global scalability and operational flexibility. The diagnostics business is also growing, with a current production capacity of 1.5 lakh kits per day, expected to increase to 4 lakh kits by the end of 2026.
Cupid Limited’s strategic focus includes strengthening its presence in international markets and expanding its product offerings. The company is the first to attain WHO/UNFPA pre-qualification for both male and female condoms and exports to over 125 countries. The diagnostics business is supported by certifications and approvals, enabling entry into European and other regulated markets.
Established in 1993, Cupid Limited is a leading manufacturer of male and female condoms, water-based lubricants, and in vitro diagnostics kits. The company is committed to public health and well-being, maintaining ethical business practices aligned with international standards. Cupid continues to expand its product offerings and enhance its production capacity to meet growing demand in both domestic and international markets.